EV-302/KEYNOTE-A39
EV-302/KEYNOTE-A39: Phase III Trial of Enfortumab Vedotin + Pembrolizumab vs Chemotherapy in Previously Untreated Locally Advanced or Metastatic Urothelial Carcinoma

Released: October 30, 2023

Activity

Progress
1
Course Completed